Reversible pancytopenia following OKT3. Use in the context of multidrug immunosuppression for kidney allografting.
We present two instances of pancytopenia in kidney transplant patients associated with a course of OKT3 therapy. In one case, OKT3 was used prophylactically, in the other therapeutically to treat biopsy-proved rejection. They both occurred in the setting of multi-drug immunosuppression, including Minnesota anti-lymphocyte globulin, and recovered with supportive therapy. Previous antihypertensive medication, antibiotics, and azathioprine were restarted without hematologic sequelae. Evidence implicating OKT3, and resultant gamma-interferon-induced marrow suppression is discussed.
Burke
G W
GW
Department of Medicine, University of Minnesota Hospital, Minneapolis 55455.
Vercellotti
G M
GM
Simmons
R L
RL
Howe
R B
RB
Canafax
D M
DM
Najarian
J S
JS
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology*; D017252:CD3 Complex; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007676:Kidney Failure, Chronic / Q000628:therapy; D016030:Kidney Transplantation; D008180:Lupus Erythematosus, Systemic / Q000628:therapy; D008875:Middle Aged; D010198:Pancytopenia / Q000209:etiology*; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000945:Antigens, Differentiation, T-Lymphocyte; D017252:CD3 Complex; D011948:Receptors, Antigen, T-Cell